GcMAF administration is typically carried out through subcutaneous (SC) or intramuscular (IM) injections, with a recommended frequency of 2-3 times per week, as directed by the attending physician. The preferred needle size for this procedure is either Size 26G x 1/2″ (0.45 x 13 mm) or Size 27G, along with a 2.5 ml or 1 ml syringe, which should be single-use and sterile disposable. It’s important to highlight that the larger 2.5 ml syringe is often preferred because it reduces the distance the plunger needs to be pushed during the injection, thus improving user-friendliness. In some cases, diabetes needles may also suffice for the administration of GcMAF, although these feature finer needles. Patients should always follow their healthcare provider’s recommendations and guidance regarding the specific administration method and equipment.
Treatment at our clinics often involves intratumoral (IT) injections, although intramuscular (IM) and subcutaneous (SC) injections are the prevailing methods of administration for the majority of our patients. It is imperative to employ a rigorous aseptic technique, which includes the use of pharmaceutical ethanol (ethyl alcohol) for swabbing the vial tops prior to needle insertion when utilizing these vials.
Alternative Methods of Administration:
Oral Administration of Oral MAF via Enteric Capsules
Saisei Mirai’s Oral MAF encapsulated in an enteric form offers an alternative method of administration specifically targeted at the Gut Associated Lymphoid Tissue (GALT).
When Oral MAF is ingested orally, enclosed within an enteric capsule designed to withstand the acidic environment of the stomach, it effectively traverses the digestive system and ultimately engages macrophages within the Peyer’s Patches located in the Gut Associated Lymphoid Tissue (GALT). It is worth noting that the gut-associated lymphoid tissue represents a substantial component, accounting for approximately 70% of the body’s immune system.
For optimal results, oral administration is recommended on an empty stomach, either in the morning, before bedtime, or approximately 30 minutes before meals. This scheduling allows for swift passage of the enteric capsule through the stomach, facilitating the targeted delivery of Oral MAF to the gut.
Oral Administration of MAF Products for Enhanced Macrophage Activation
The oral administration of MAF (Macrophage Activation Factor) products, such as Oral MAF powder and MAF candies, presents a unique approach to harnessing the immune-boosting potential within the lymphoid tissue of the mouth and throat. This tissue is rich in macrophages, immune cells that play a pivotal role in defending the body against infections and foreign agents.
When we employ the use of Oral MAF powder and Oral MAF Capsules (by opening the capsules), the macrophages within the mouth and throat can be effectively activated. This activation is achieved by allowing the powder to rest in the mouth for a period of 15-20 minutes or longer. Alternatively, macrophage activation can also be stimulated by consuming MAF candies.
While there is the possibility of sublingual absorption of some GcMAF through the blood vessels in the mouth, the primary method of activation is believed to occur within the lymphoid tissue of the throat. This lymphoid tissue is a vital component of the immune system, crucial for mounting immune responses and safeguarding the body against infections and foreign invaders.
This method of administration holds particular promise for individuals with deficiencies in Immunoglobulin A (IgA) and Immunoglobulin M (IgM), as it offers a targeted approach to bolstering their immune defenses. By leveraging the lymphoid tissue’s innate capacity for macrophage activation, Oral MAF products can contribute to improving immune function and overall health.
Inhalation via Nebulization:
Another viable option for GcMAF administration involves utilizing a nebulizer to stimulate macrophages within the bronchus-associated lymphoid tissue (BALT) of the lungs. This approach entails the use of specialized devices like the Omron NE-U22 Portable Nebulizer. It is especially advantageous for lung-related disorders, as local administration can yield more pronounced therapeutic effects.
| Omron NE-U22 Portable Nebuliser for administration in the lungs to activate macrophages in the Bronchus-Associated Lymphoid Tissue (BALT) of the lungs. |